Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Rises By 24.0%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,550,000 shares, a growth of 24.0% from the March 15th total of 1,250,000 shares. Approximately 3.2% of the company’s shares are sold short. Based on an average daily trading volume, of 2,210,000 shares, the short-interest ratio is presently 0.7 days.

Cardio Diagnostics Price Performance

Shares of Cardio Diagnostics stock traded down $0.01 during midday trading on Monday, reaching $0.38. 126,382 shares of the company’s stock traded hands, compared to its average volume of 2,557,702. The stock has a 50 day moving average of $0.43 and a 200-day moving average of $0.49. Cardio Diagnostics has a 12 month low of $0.19 and a 12 month high of $1.77.

Institutional Investors Weigh In On Cardio Diagnostics

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Cardio Diagnostics by 97.6% in the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after buying an additional 179,978 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of Cardio Diagnostics in the 4th quarter valued at approximately $48,000. Jane Street Group LLC bought a new stake in shares of Cardio Diagnostics during the fourth quarter valued at approximately $103,000. Finally, Millennium Management LLC purchased a new stake in Cardio Diagnostics in the fourth quarter worth $236,000. 8.06% of the stock is owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.